Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lianhua Qingwen for asymptomatic COVID-19 infection
ChiCTR2100042066Phase 4Recruiting
- Sponsor
- Hebei Province Chest Hospital
- Start
- Jan 2021
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Lianhua Qingwen in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hebei Province Chest Hospital. Primary endpoints: Time to negative SARS-CoV-2 nucleic acid test during isolation observation and Rate of negative SARS-CoV-2 nucleic acid test during isolation observation. Started Jan 2021; status: recruiting.
02
Drugs
Lianhua Qingwen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100042066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042066.